There are 108 resources available
LBA39 - 3-years follow-up of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus xevinapant or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck
Presenter: Jean Bourhis
Session: Proffered Paper - Head & Neck cancer
Resources:
Abstract
Slides
Webcast
LBA40 - Neoadjuvant nivolumab and nivolumab plus ipilimumab induce (near-) complete responses in patients with head and neck squamous cell carcinoma: The IMCISION trial
Presenter: Lotje Zuur
Session: Proffered Paper - Head & Neck cancer
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA28 and 806O
Presenter: Domenica Lorusso
Session: Proffered Paper - Gynaecological cancers 1
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Domenica Lorusso
Session: Proffered Paper - Gynaecological cancers 1
Resources:
Webcast
Invited Discussant LBA29 and LBA30
Presenter: Andreas du Bois
Session: Proffered Paper - Gynaecological cancers 1
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Domenica Lorusso
Session: Proffered Paper - Gynaecological cancers 1
Resources:
Webcast
1670O - Prospective data of first 1,797 hospitalised patients with cancer and COVID-19 derived from the COVID-19 Clinical Information Network and international Severe Acute Respiratory and emerging Infections Consortium, WHO Coronavirus Clinical Characterisation Consortium
Presenter: Carlo Palmieri
Session: Proffered Paper - SARS-CoV-2 and cancer 1
Resources:
Abstract
Slides
Webcast
396O - Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Phase III KEYNOTE-177 study
Presenter: Thierry André
Session: Proffered Paper - GI, colorectal
Resources:
Abstract
Slides
Webcast
397O - Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy: The phase II CAVE (cetuximab-avelumab) mCRC study
Presenter: Erika Martinelli
Session: Proffered Paper - GI, colorectal
Resources:
Abstract
Slides
Webcast
398O - Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer (CRC) - PRODIGE 13 a FFCD phase III trial
Presenter: Come Lepage
Session: Proffered Paper - GI, colorectal
Resources:
Abstract
Slides
Webcast